



VIA HAND DELIVERY APRIL 10TH, 2003

Docket No.: PF514P1
(PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:
Baker et al

Application No.: 10/073,333

Filed: February 13, 2002

For: HUMAN TUMOR NECROSIS FACTOR
RECEPTOR TR16

Group Art Unit: 1646

Examiner: E. O'Hara

#11
J.G.
4/16/03
RECEIVED

APR 15 2003

TECH CENTER 1600/2900

INFORMATION DISCLOSURE STATEMENT PURSUANT TO 37 C.F.R. § 1.56

Commissioner for Patents
Washington, D.C. 20231

Sir:

In accordance with the duty of disclosure imposed by 37 C.F.R. § 1.56 to inform the Patent and Trademark Office of all references coming to the attention of each individual associated with the filing or prosecution of the subject application, which are or may be material to the patentability of an claim of the subject application, Applicants hereby direct the Examiner's attention to the references AA-BA listed on the attached revised Form PTO/SB/08.

Copies of references AA-BA were submitted by Applicants or cited by the Examiner in connection with United States Patent Application Serial No. 09/637,856 filed August 10, 2000, to which the instant application claims priority under 35 U.S.C. § 120. Pursuant to 37 C.F.R. § 1.98(d), the Examiner is respectfully directed to the file of United States Patent Application Serial No. 09/637,856 for copies of references AA-BA.

Applicants also wish to bring to the attention of the Examiner that SEQ ID NOs:1 and 3 and the corresponding cDNA clones of the present application are related to SEQ ID NO:2571 in copending U.S. Application Serial No. 09/912,293. A legible copy of that portion of U.S. Patent Application Serial No. 09/912,293 which caused it to be listed on the attached form PTO/SB/08 was previously submitted on December 3, 2001, by

Applicants in connection with United States Patent Application Serial No. 09/637,856, as reference AB.


Applicants respectfully request that the Examiner review the materials identified above and that they be made of record in the file history of the application.

Identification of the materials identified above is not to be construed an admission of any individual associated with the filing or prosecution of the subject application that any such material is available as "prior art" against the subject application. Furthermore, Applicants do not waive any rights to appropriate action to establish patentability over any of the listed documents should they be applied as references against the claims of the subject application.

In accordance with 37 C.F.R. § 1.97(b)(3), since it is believed that this Information Disclosure Statement is being filed before the mailing date of a first Office Action on the merits, no fee is believed due in connection herewith. However, should the Patent Office determine otherwise, please charge the required fee to Human Genome Science, Inc., Deposit Account No. 08-3425. A copy of this sheet is enclosed.

Respectfully submitted,

Date: April 10, 2003



Lin J. Hymel (Reg. No. 45,414)
Attorney for Applicants
Human Genome Sciences, Inc.
9410 Key West Avenue
Rockville, MD 20850
(301) 251-6015 (telephone)

KKH/LJH/BM
Enclosures